News & Presentations

Umoja Biopharma Announces Appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer
June 7, 2021

Seattle, WA, June 8, 2021– Umoja Biopharma, a leading oncology company leveraging its proprietary, integrated technologies to reprogram immune cells directly in the human body to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer.

READ MORE >

Umoja Biopharma Announces Appointment of Dr. Irena Melnikova as Chief Financial Officer
May 17, 2021

Umoja Biopharma, a biotechnology company pioneering an integrated, in vivo immunotherapy platform, today announced the appointment of Irena Melnikova, Ph.D., as Chief Financial Officer.

READ MORE >

Umoja Biopharma Appoints Renowned Oncologist and Industry Leader Dr. Nushmia Khokhar as Chief Medical Officer
April 6, 2021

Umoja Biopharma, a biotechnology company pioneering an integrated, in vivo immunotherapy platform, today announced the appointment of Nushmia Khokhar, M.D., as Chief Medical Officer.

READ MORE >

Umoja Biopharma Appoints Dr. Robert Glassman to its Board of Directors
January 25, 2021

Umoja Biopharma, a biotechnology company pioneering an integrated, in vivo immunotherapy platform, today announced the appointment of Rob Glassman, M.D., to its Board of Directors.

READ MORE >

Umoja Biopharma Launches with $53M Series A Financing to Develop Fully Integrated, Scalable, In Vivo Immunotherapy Platform
November 18, 2020

Umoja’s platform addresses key limitations of existing engineered immunotherapies. Company backed by prominent life science investors MPM Capital, DCVC Bio and Qiming Venture Partners USA and led by an experienced team of scientist/entrepreneurs.

READ MORE >

We are led by a world class team that operates on a foundation of respect for the contributions of everyone on the Umoja team.